Author

Ruba Deeb Bou-Chahine

Observed name: Ruba Bou-Chahine

Institutions: AstraZeneca (Brazil), Alexion Pharma (Switzerland)

Observed institutions: AstraZeneca (Brazil), Alexion Pharma (Switzerland)

OpenAlex ID: A5095065899

Innate Immune Dysregulation Precedes Clinical Onset in Neuromyelitis Optica

2026 · Leonie Muller-Jensen, Debanjana Chakravarty, et al. · bioRxiv (Cold Spring Harbor Laboratory)

Astrocytic and Axonal Injury Biomarkers in AQP4 Antibody–Positive NMOSD

2026 · Dean M. Wingerchuk, Jeffrey L. Bennett, et al. · Neurology Neuroimmunology & Neuroinflammation

Gene Expression Signatures Associated with Prior Rituximab Treatment in Patients with Anti-aquaporin-4 Antibody-positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD) in the CHAMPION-NMOSD Trial (S6.007)

2026 · Sean Pittock, Irem Celen, et al. · Neurology

Clinical Characteristics Associated With High Baseline Glial Fibrillary Acidic Protein (GFAP) and Neurofilament Light Chain (NfL) Levels in Patients With Anti-Aquaporin-4 Antibody-Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD) From the PREVENT and CHAMPION-NMOSD Trials (S38.001)

2025 · Dean Wingerchuk, Jeffrey Bennett, et al. · Neurology

Evaluation of Glial Fibrillary Acidic Protein (GFAP) and Neurofilament Light Chain (NfL) Levels During Eculizumab and Ravulizumab Treatments in Anti-Aquaporin-4-Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD)

2024 · Dean Wingerchuk, Jeffrey Bennett, et al. · Neurology

Evaluation of Glial Fibrillary Acidic Protein (GFAP) and Neurofilament Light Chain (NfL) Levels During Eculizumab and Ravulizumab Treatments in Aquaporin-4-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) (S32.004)

2024 · Dean Wingerchuk, Jeffrey Bennett, et al. · Neurology

Works count: 6

Citation count:

H-index:

I10-index: